person
Iuliana Angelica T. C.
- Country
- Belgium
- Department
- Medical oncology
Research Overview
assignment
3
Clinical Trials ·
- Efficacy and Safety of GDC-6036 Versus Sotorasib or Adagrasib in KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
- Evaluation of Alectinib and Chemotherapy Efficacy and Safety in Resectable Stage I-III ALK-Positive Non-Small Cell Lung Cancer Patients
- Efficacy and Safety of Divarasib and Pembrolizumab vs. Pembrolizumab with Pemetrexed and Carboplatin or Cisplatin in KRAS G12C-Mutated NSCLC
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
63
Sites with multiple studies
Has run more than one trial at 63 of 170 partner sites.
Specializations
Lung Cancer Research
This investigator specializes in the study of advanced non-small cell lung cancer (NSCLC), with particular emphasis on cases involving KRAS G12C mutations.
- Advanced Stage Lung Cancer
- Metastatic NSCLC
- KRAS Mutations
Targeted Therapies
The investigator focuses on evaluating novel therapeutic approaches targeting KRAS G12C inhibition in lung cancer treatment, including emerging targeted therapies.
- KRAS G12C Inhibitors
- Molecular Targeted Therapy
- Treatment Resistance
Treatment Comparisons
Expertise in conducting comparative analyses of different therapeutic interventions for advanced lung cancer, with a focus on progression-free survival outcomes.
- Therapeutic Efficacy
- Safety Assessment
- Clinical Outcomes
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.